ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Britain’s decision to exit the European Union isn’t stopping GlaxoSmithKline from deciding to invest more than $350 million at three of its U.K. sites to boost production of new respiratory therapies and biologic medicines. GSK, which employs about 6,000 at nine U.K. manufacturing locations, will expand in Barnard Castle in County Durham, England; Montrose in Angus, Scotland; and Ware in Hertfordshire, England. The company says most of the products will be exported around the world.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter